(1992) described the IGF-1 LR3 analog and documented its dramatically reduced IGFBP binding compared to native IGF-1, establishing the pharmacokinetic rationale for its use as a research tool (PMID 1601853)
Rapid power loss or failure to deliver full capacity
Science advances through critical verification rather than by repeatedly affirming findings within the same research group, a team of scientists in Poland wrote in response to Sikirics BPC157 claims
Theyre wanting a certain amount of certitude that, frankly, is appropriate for most drugs, but not for this moment. Regulatory shortcuts exist that would allow the FDA to skip the more laborious approval process
Vitamin C Acts as a cofactor for hydroxylase enzymes that cross-link collagen fibers, strengthens dermal structure, and neutralizes UV-induced oxidative damage to skin cells
Non-covalent inhibitors of thioredoxin glutathione reductase with schistosomicidal activity in vivo